Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review

European Journal of Cancer

Volumn 39, Issue 16, 2003, Pages 2288-2297

  Morse, R ^a   Rodgers, J ^a   Verrill, M ^b   Kendell, K ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cognitive deficits; Tamoxifen

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; MYELOABLATIVE AGENT; TAMOXIFEN;

ACADEMIC ACHIEVEMENT; AGE DISTRIBUTION; APTITUDE TEST; ATTENTION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; COGNITIVE DEFECT; DRUG MEGADOSE; ESTROGEN BLOOD LEVEL; ESTROGEN RELEASE; ESTROGEN SYNTHESIS; EVALUATION; FOLLOW UP; HOT FLUSH; HUMAN; INTELLIGENCE QUOTIENT; INTELLIGENCE TEST; LIFE EXPECTANCY; LONG TERM MEMORY; LONGITUDINAL STUDY; MENOPAUSE; MENTAL FUNCTION; MENTAL STRESS; MENTAL TASK; NEUROPSYCHOLOGY; NEUROTOXICITY; POSTMENOPAUSE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; REVIEW; SAMPLE SIZE; SKILL; SOCIOECONOMICS; SURVIVAL RATE; VERBAL MEMORY;

EID: 0141706599     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00600-2     Document Type: Article

References (36)

1. Tierney A.J., Taylor J., Closs S.J. Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer. Scandan J. Caring Sci. 6:1992;75-80.
2. Bender C.M., Paraska K.K., Sereika S.M.et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer. a critical review J. Pain Symptom Manage. 21:2001;407-424.
3. Olin J.J. Cognitive function after systemic therapy for breast cancer. Oncology. 15:2001;613-618.
4. Phillips K., Bernhard J. Adjuvant breast cancer treatment and cognitive function. current knowledge and research directions J. Natl. Cancer Inst. 95:2003;190-197.
5. Ahles T.A., Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 19:2001;812-820.
6. Beisecker A., Cook M.R., Ashworth J.et al. Side effects of adjuvant chemotherapy. perceptions of node-negative breast cancer patients Psychooncology. 6:1997;85-93.
7. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
8. Wieneke M., Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 4:1995;61-66.
9. Van Dam F., Schagen S.B., Muller M.J.et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer. high-dose versus standard-dose chemotherapy J. Natl. Cancer Inst. 90:1998;210-218.
10. Schagen S.B., van Dam F., Muller M.J.et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 85:1999;640-650.
11. Brezden C.B., Phillips K.A., Abdolell M.et al. Cognitive functioning in breast cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 18:2000;2695-2701.
12. Ahles T.A., Saykin A.J., Furstenberg C.T.et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 20:2002;485-493.
13. Schagen S.B., Muller M.J., Boogerd W.et al. Late effects of adjuvant chemotherapy on cognitive function. a follow-up study in breast cancer patients Ann. Oncol. 13:2002;1387-1397.
14. Paganini-Hill A., Clark L.J. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 64:2000;165-176.
15. Ernst T., Chang L., Cooray D.et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J. Natl. Cancer Inst. 94:2002;592-597.
16. Gianni L. Editorial. High-dose chemotherapy for breast cancer: any use for it? Ann. Oncol. 13:2002;650-652.
17. Polychemotherapy for early breast cancer: an overview of the randomised trails. Lancet. 352:1998;930-942.
18. Shilling V., Jenkins V., Fallowfield L., Howell A. The effects of oestrogens and anti-oestrogens on cognition. Breast. 10:2001;484-491.
19. Shughrue P.J., Lane M.V., Merchenthaler I. Comparative distribution of estrogen receptor alpha and beta mRNA in the rat central nervous system. J. Comp. Neurol. 388:1997;507-525.
20. Sherwin B.B., Estrogen cognitive functioning in Women P. Soc. Exp. Biol. Med. 217:1998;17-22.
21. Kritz-Silverstein D., Barrett-Connor E. Hysterectomy, oophorectomy, and cognitive function in older women. J. Am. Geriatr. Soc. 50:2002;55-61.
22. Fisher B., Constantino J.P., Lawrence D.et al. Tamoxifen for prevention of breast cancer. report of the national surgical adjuvant breast and bowel project P-1 study J. Natl. Cancer Inst. 90:1998;1371-1388.
23. Dhingra K. Antiestrogens - tamoxifen, SERMs and beyond. Invest. New Drugs. 17:1999;285-311.
24. Chen D., Chun F.U., Shi B., Xu Y.M. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol. Biochem. Behav. 71:2002;277-284.
25. Ganz P.A., Castellion S.A., Silverman D.H.S. Editorial. Estrogen, tamoxifen, and the brain J. Natl. Cancer Inst. 94:2002;547-549.
26. Yaffe K., Krueger K., Sarjkar S., Grady D., Barrett-Connor E., Cox D., Nickelsen T. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 244:2001;1207-1213.
27. Bernstein S.G., Vardy M.D., Nieves J., Ferrara K., Lindsay R., Cosman F. Short-term effects of raloxifene, tamoxifen, and estrogen on cognitive function. Obstetrics Gynaecol. 99:2002;S59-S60.
28. Baum M., Buzdar A.U., Cuzick J.et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early breast cancer. first results of the ATAC randomised trial Lancet. 359:2002;2131-2139.
29. Shilling V., Jenkins V., Fallowfield L., Howell T. Cognitive assessment of women receiving hormone therapy for breast cancer. Psychooncology. 11:2002;556. (abstr.).
30. Wilson B., Cockburn J., Baddeley A.et al. The development and validation of a test battery for detecting and monitoring everyday memory problems. J. Clin. Exp. Neuropsyc. 11:1989;855-870.
31. LeBlanc E.S., Janowsky J., Chan B.K.S., Nelson H.D. Hormone replacement therapy and cognition. a systematic review and meta-analysis JAMA. 285:2001;1489-1499.
32. Haskell S.G., Richardson E.D., Horwitz R.I. The effect of estrogen replacement therapy on cognitive function in women. a critical review of the literature J. Clin. Epidemiol. 50:1997;1249-1264.
33. Band G.P.H., Ridderinkhof K.R., Segalowitz S. Explaining neurocognitive aging. is one factor enough? Brain Cognition. 49:2002;259-267.
34. Sellick S.M., Crooks D.L. Depression and cancer. an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions Psychooncology. 8:1999;315-333.
35. Eysenck M.W. Anxiety: The Cognitive Perspective. 1992;Erlbaum, Hillsdale, NJ.
36. Grober S.E. Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Practice. 10:2002;216-218.